Matrix metalloproteinases in head and neck cancer: current perspectives

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.
   PubMed Web of Science ®Google Scholar
• Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86(2):104–114.
   PubMed Web of Science ®Google Scholar
• Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009;45(4–5):324–334.
   PubMed Web of Science ®Google Scholar
• Ruzevick J, Olivi A, Westra WH. Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol. 2013;112(3):449–454.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27.
   PubMed Web of Science ®Google Scholar
• Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015;44–46:200–206.
   Web of Science ®Google Scholar
• Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 2015;44–46:184–190.
   Web of Science ®Google Scholar
• Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494.
   PubMed Web of Science ®Google Scholar
• Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4(7):544–558.
   PubMed Web of Science ®Google Scholar
• Ala-Aho R, Kähäri VM. Collagenases in cancer. Biochimie. 2005;87(3–4):273–286.
   PubMed Web of Science ®Google Scholar
• Syggelos SA, Aletras AJ, Smirlaki I, Skandalis SS. Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome. Biomed Res Int. 2013;2013:230805.
   Web of Science ®Google Scholar
• Lee JT, Pamir N, Liu NC, et al. Macrophage metalloelastase (MMP12) regulates adipose tissue expansion, insulin sensitivity, and expression of inducible nitric oxide synthase. Endocrinology. 2014;155(9):3409–3420.
   Web of Science ®Google Scholar
• Itoh Y. Membrane-type matrix metalloproteinases: their functions and regulations. Matrix Biol. 2015;44–46:207–223.
   Web of Science ®Google Scholar
• Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95(3):365–377.
   Web of Science ®Google Scholar
• Hotary KB, Yana I, Sabeh F, et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med. 2002;195(3):295–308.
   Web of Science ®Google Scholar
• Eckhard U, Huesgen PF, Schilling O, et al. Active site specificity profiling of the matrix metalloproteinase family: proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol. 2016;49:37–60.
   PubMed Web of Science ®Google Scholar
• Llano E, Pendás AM, Knäuper V, et al. Identification and structural and functional characterization of human enamelysin. J Biol Chem. 1997;36(49):15101–15108.
   Google Scholar
• Bartlett JD, Ryu OH, Xue J, Simmer JP, Margolis HC. Enamelysin mRNA displays a developmentally defined pattern of expression and encodes a protein which degrades amelogenin. Connect Tissue Res. 1998;39(1–3):101–109.
   PubMed Web of Science ®Google Scholar
• Begue-Kirn C, Krebsbach PH, Bartlett JD, Butler WT. Dentin sialoprotein, dentin phosphoprotein, enamelysin and ameloblastin: tooth-specific molecules that are distinctively expressed during murine dental differentiation. Eur J Oral Sci. 1998;106(5):963–970.
   PubMed Web of Science ®Google Scholar
• Hu Y, Smith CE, Richardson AS, Bartlett JD, Hu JC, Simmer JP. MMP20, KLK4, and MMP20/KLK4 double null mice define roles for matrix proteases during dental enamel formation. Mol Genet Genomic Med. 2015;4(2):178–196.
   Web of Science ®Google Scholar
• Saxena G, Koli K, de la Garza J, Ogbureke KU. Matrix metalloproteinase 20-dentin sialophosphoprotein interaction in oral cancer. J Dent Res. 2015;94(4):584–593.
   Web of Science ®Google Scholar
• Koli K, Saxena G, Ogbureke KU. Expression of matrix metalloproteinase (MMP)-20 and potential interaction with dentin sialophosphoprotein (DSPP) in human major salivary glands. J Histochem Cytochem. 2015;63(7):524–533.
   Web of Science ®Google Scholar
• Ogbureke KU, Koli K, Saxena G. Matrix metalloproteinase 20 co-expression with dentin sialophosphoprotein in human and monkey kidneys. J Histochem Cytochem. 2016;64(10):623–636.
   Web of Science ®Google Scholar
• Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211(1):19–26.
   PubMed Web of Science ®Google Scholar
• Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9–10):342–359.
   PubMedGoogle Scholar
• Attard G, Ang JE, Olmos D, de Bono JS. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J Clin Pathol. 2008;61(8):891–896.
   Web of Science ®Google Scholar
• Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS One. 2012;7(8):e42507.
   Web of Science ®Google Scholar
• Yao Y, Ma J, Xue Y, et al. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein. Mol Oncol. 2015;9(3):640–656.
   Web of Science ®Google Scholar
• Hall MC, Young DA, Waters JG, et al. The comparative role of activator protein 1 and Smad factors in the regulation of TIMP-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem. 2003;278(12):10304–10313.
   PubMed Web of Science ®Google Scholar
• Benderdour M, Tardif G, Pelletier JP, Dupuis M, Geng C, Martel-Pelletier J. A novel negative regulatory element in the human collagenase-3 proximal promoter region. Biochem Biophys Res Commun. 2002;291(5):1151–1159.
   Web of Science ®Google Scholar
• Arendt Y, Banci L, Bertini I, et al. Catalytic domain of MMP20 (enamelysin): the NMR structure of a new matrix metalloproteinase. FEBS Lett. 2007;581(24):4723–4726.
   Web of Science ®Google Scholar
• Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498–509.
   PubMed Web of Science ®Google Scholar
• Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34(4):233–242.
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5):290–308.
   PubMed Web of Science ®Google Scholar
• Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J. 2004;18(6):734–736.
   PubMedGoogle Scholar
• Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280(2):460–465.
   PubMed Web of Science ®Google Scholar
• Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(1):26–34.
   PubMed Web of Science ®Google Scholar
• Mi YY, Zhang LF, Zhu LJ. MMP7-181G allele is a low-penetrant risk factor for cancer development in East Asians. DNA Cell Biol. 2012;31(5):772–776.
   Web of Science ®Google Scholar
• Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, et al. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet. 2008;46(3–4):137–144.
   Web of Science ®Google Scholar
• Li Y, Sun DL, Duan YN, et al. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of north China. Mol Biol Rep. 2010;37(1):197–205.
   Web of Science ®Google Scholar
• Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010;25(4):371–379.
   PubMed Web of Science ®Google Scholar
• Li X, Qu L, Zhong Y, Zhao Y, Chen H, Daru L. Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol. 2013;139(9):1433–1447.
   Web of Science ®Google Scholar
• Yang TF, Guo L, Wang Q. Meta-analysis of associations between four polymorphisms in the matrix metalloproteinases gene and gastric cancer risk. Asian Pac J Cancer Prev. 2014;15(3):1263–1267.
   Google Scholar
• Yang X, Hu JW, Qiu MT, et al. Association of matrix metalloproteinase-3-1171(5A>6A) polymorphism with cancer risk: a meta-analysis of 41 studies. PLoS One. 2014;9(1):e87562.
   Web of Science ®Google Scholar
• Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 2010;1803(1):39–54.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sheng S, Zhang J, et al. Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One. 2013;8(5):e63581.
   Web of Science ®Google Scholar
• Saleh A, Stathopoulou MG, Dadé S, et al. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet. 2015;16:90.
   PubMed Web of Science ®Google Scholar
• Iizuka S, Ishimaru N, Kudo Y. Matrix metalloproteinases: the gene expression signatures of head and neck cancer progression. Cancers (Basel). 2014;6(1):396-415.
   PubMed Web of Science ®Google Scholar
• Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006;28(7):639–648.
   Web of Science ®Google Scholar
• Nagata M, Fujita H, Ida H, et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer. 2003;106(5):683–689.
   Web of Science ®Google Scholar
• Chung CH, Parker JS, Karaka G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500.
   PubMed Web of Science ®Google Scholar
• Ye H, Yu T, Temam S, et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics. 2008;9:69.
   PubMed Web of Science ®Google Scholar
• Omar AA, Haglund C, Virolainen S, et al. MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(4):459–467.
   Web of Science ®Google Scholar
• Ogbureke KU, Nikitakis NG, Warburton G, et al. Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol. 2007;43(9):920–932.
   Web of Science ®Google Scholar
• Yamakoshi Y, Hu JC, Iwata T, Kobayashi K, Fukae M, Simmer JP. Dentin sialophosphoprotein is processed by MMP-2 and MMP-20 in vitro and in vivo. J Biol Chem. 2006;281:38235–38243.
   PubMed Web of Science ®Google Scholar
• Rosenthal EL, McCrory A, Talbert M, Carroll W, Magnuson JS, Peters GE. Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch Otolaryngol Head Neck Surg. 2004;130(8):943–947.
   Google Scholar
• Lotfi A, Mohammadi G, Tavassoli A, Mousaviagdas M, Chavoshi H, Saniee L. Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2015;16(4):1327–1330.
   PubMedGoogle Scholar
• Tadbir AA, Purshahidi S, Ebrahimi H, et al. Serum level of MMP-3 in patients with oral squamous cell carcinoma: lack of association with clinico-pathological features. Asian Pac J Cancer Prev. 2012;13(9):4545–4548.
   Google Scholar
• Chang PY, Kuo YB, Wu TL, et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer. Clin Chem Lab Med. 2013;51(6):1291–1300.
   Web of Science ®Google Scholar
• Pereira AC, do Carmo ED, da Silva MA, Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent. 2012;4(5):e297–e301.
   Google Scholar
• Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.
   PubMed Web of Science ®Google Scholar
• Chaudhary AK, Pandya S, Mehrotra R, Bharti AC, Jain S, Singh M. Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers. 2010;15(8):684–692.
   Web of Science ®Google Scholar
• Vairaktaris E, Vassiliou S, Nkenke E, et al. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol. 2008;34(4):450–455.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang L, Luo H, Zhu Z, Zhang C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27(10):553–557.
   Web of Science ®Google Scholar
• Vairaktaris E, Yapijakis C, Vasiliou S, et al. Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res. 2007;27(6B):4095–4100.
   PubMed Web of Science ®Google Scholar
• Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med. 2007;36(7):409–414.
   Web of Science ®Google Scholar
• Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med. 2004;33(7):405–409.
   Web of Science ®Google Scholar
• Nair RR, Avila H, Ma X, et al. A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol. 2008;73(3):919–929.
   Web of Science ®Google Scholar
• Bedal KB, Grässel S, Oefner PJ, Reinders J, Reichert TE, Bauer R. Collagen XVI induces expression of MMP9 via modulation of AP-1 transcription factors and facilitates invasion of oral squamous cell carcinoma. PloS One. 2014;9(1):e86777.
   Web of Science ®Google Scholar
• Lee EJ, Whang JH, Jeon NK, Kim J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann N Y Acad Sci. 2007;1095:113–128.
   Web of Science ®Google Scholar
• Suzuki S, Ishikawa K. Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells. Int J Oncol. 2014;44(3):912–917.
   Web of Science ®Google Scholar
• Chen HJ, Lin CM, Lee CY, et al. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling. Int J Oncol. 2013;43(2):629–637.
   Web of Science ®Google Scholar
• O-Charoenrat P, Rhys-Evans P, Eccles S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer. 2002;100(5):527–533.
   Web of Science ®Google Scholar
• Dang D, Yang Y, Li X, et al. Matrix metalloproteinases and TGFβ1 modulate oral tumor cell matrix. Biochem Biophys Res Comm. 2004;316(3):937–942.
   Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol. 2012;2012:564259.
   PubMedGoogle Scholar
• Mohtasham N, Babakoohi S, Shiva A, et al. Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract. 2013;209(2):110–114.
   PubMed Web of Science ®Google Scholar
• Zuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem. 2011;112(9):2508–2517.
   PubMed Web of Science ®Google Scholar
• Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825(1):29–36.
   PubMed Web of Science ®Google Scholar
• Van Tubergen EA, Banerjee R, Liu M, et al. Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6. Clin Cancer Res. 2013;19(5):1169–1179.
   Web of Science ®Google Scholar
• Munshi HG, Wu YI, Ariztia EV, Stack MS. Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem. 2002;277(44):41480–41488.
   Web of Science ®Google Scholar
• Singh RD, Haridas N, Patel JB, et al. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem. 2010;25(3):250–259.
   Google Scholar
• Huang Z, Tan N, Guo W, et al. Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasis. PloS One. 2014;9(4):e91596.
   Web of Science ®Google Scholar
• Liang X, Yang X, Tang Y, et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncol. 2008;44(12):1172–1180.
   Web of Science ®Google Scholar
• Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T, Nakanishi O. The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis. 2011;17(5):462–468.
   Web of Science ®Google Scholar
• Deraz EM, Kudo Y, Yoshida M, et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PloS One. 2011;6(10):e25438.
   PubMed Web of Science ®Google Scholar
• Chuang JY, Tsai CF, Chang SW, et al. Glial cell line-derived neurotrophic factor induces cell migration in human oral squamous cell carcinoma. Oral Oncol. 2013;49(12):1103–1112.
   Web of Science ®Google Scholar
• Wang H, Wu Q, Liu Z, et al. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 2014;5:e1155.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
   PubMed Web of Science ®Google Scholar
• Radisky ES, Radisky DC. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed). 2015;20:1144–1163.
   PubMed Web of Science ®Google Scholar
• Sounni NE, Paye A, Host L, Noël A. MT-MMPS as regulators of vessel stability associated with angiogenesis. Front Pharmacol. 2011;2:111.
   Web of Science ®Google Scholar
• Sil H, Chatterjee A. Integrin alpha-V beta-3-matrix metalloproteinase-2 (MMP-2), cross-talk. J Cancer Ther. 2015;6(9):793–802.
   Google Scholar
• Shiomi T, Lemaître V, D’Armiento J, Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int. 2010;60(7):477–496.
   PubMed Web of Science ®Google Scholar
• Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int. 2015;2015:690690.
   PubMed Web of Science ®Google Scholar
• Dey N, Young B, Abramovitz M, et al. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One. 2013;8(10):e77425.
   Web of Science ®Google Scholar
• Lu H, Yang Z, Zhang H, Gan M, Zhou T, Wang S. The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Exp Ther Med. 2013;5(3):890–896.
   Web of Science ®Google Scholar
• Jimenez L, Jayakar SK, Ow TJ, Segall JE. Mechanisms of invasion in head and neck cancer. Arch Pathol Lab Med. 2015;139(11):1334–1348.
   Web of Science ®Google Scholar
• Kim JM, Kim HJ, Koo BS, Rha KS, Yoon YH. Expression of matrix metalloproteinase-12 is correlated with extracapsular spread of tumor from nodes with metastasis in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2013;270(3):1137–1142.
   Web of Science ®Google Scholar
• Yu G, Herazo-Maya JD, Nukui T, et al. Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. Am J Respir Crit Care Med. 2014;190(7):780–790.
   Web of Science ®Google Scholar
• Stratman AN, Davis GE. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal. 2012;18(1):68–80.
   PubMed Web of Science ®Google Scholar
• Onimaru M, Yonemitsu Y, Suzuki H, Fujii T, Sueishi K. An autocrine linkage between matrix metalloproteinase-14 and Tie-2 via ectodomain shedding modulates angiopoietin-1-dependent function in endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30(4):818–826.
   Web of Science ®Google Scholar
• Ugarte-Berzal E, Vandooren J, Bailon E, Opdenakker G, Garcia-Pardo A. l. Inhibition of MMP-9-dependent degradation of gelatin, but not other MMP-9 substrates, by the MMP-9 hemopexin domain blades 1 and 4. J Biol Chem. 2016;291(22):11751–11760.
   Web of Science ®Google Scholar
• Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 2015;44–46:184–190.
   Web of Science ®Google Scholar
• Cha H, Kopetzki E, Huber R, Lanzendörfer M, Brandstetter H. Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol. 2002;320(5):1065–1079.
   Web of Science ®Google Scholar
• Piccard H, Van den Steen PE, Opdenakker G. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol. 2007;81(4):870–892.
   Web of Science ®Google Scholar
• Redondo-Muñoz J, Ugarte-Berzal E, Garcia-Marco JA, et al. α4β1 Integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood. 2008;112(1):169–178.
   PubMed Web of Science ®Google Scholar
• Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK. The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem. 2001;276(18):15498–15503.
   Web of Science ®Google Scholar
• Van den Steen PE, Van Aelst I, Hvidberg V, et al. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem. 2006;281(27):18626–18637.
   PubMed Web of Science ®Google Scholar
• Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992;267(7):4583–4591.
   PubMed Web of Science ®Google Scholar
• Butler GS, Apte SS, Willenbrock F, Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B: regulation by polyanions. J Biol Chem. 1999;274(16):10846–10851.
   Web of Science ®Google Scholar
• Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grötzinger J, Roeb E. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol. 2007;30(4):985–992.
   Web of Science ®Google Scholar
• Roeb E, Schleinkofer K, Kernebeck T, et al. The matrix metalloproteinase 9 (MMP-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem. 2002;277(52):50326–50332.
   Web of Science ®Google Scholar
• Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, et al. A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J Biol Chem. 2012;287(33):27601–27613.
   PubMed Web of Science ®Google Scholar
• Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Albar JP, García-Marco JA, García-Pardo A. A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells. J Biol Chem. 2014;289(22):15340–15349.
   Web of Science ®Google Scholar
• Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle. 2008;7(8):1047–1053.
   PubMed Web of Science ®Google Scholar
• Dufour A, Sampson NS, Zucker S, Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol. 2008;217(3):643–651.
   Web of Science ®Google Scholar
• Radjabi AR, Sawada K, Jagadeeswaran S, et al. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and β1-integrin on the cell surface. J Biol Chem. 2008;283(5):2822–2834.
   Web of Science ®Google Scholar
• Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem. 2009;284(38):25854–25866.
   PubMed Web of Science ®Google Scholar
• Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene. 2005;24(5):859–868.
   Web of Science ®Google Scholar
• Eisenach PA, Roghi C, Fogarasi M, Murphy G, English WR. MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 2010;123(Pt 23):4182–4193.
   Web of Science ®Google Scholar
• Zarrabi K, Dufour A, Li J, et al. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem. 2011;286(38):33167–33177.
   PubMed Web of Science ®Google Scholar
• Correia AL, Mori H, Chen EI, Schmitt FC, Bissell MJ. The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90beta. Genes Dev. 2013;27(7):805–817.
   Web of Science ®Google Scholar
• Song X, Wang X, Zhuo W, et al. The regulatory mechanism of extracellular Hsp90α on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem. 2010;285(51):40039–40049.
   Web of Science ®Google Scholar
• Galea CA, Nguyen HM, Chandy KG, Smith BJ, Norton RS. Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking. Cell Mol Life Sci. 2014;71(7):1191–1210.
   Web of Science ®Google Scholar
• Wiegand S, Dünne AA, Müller HH, et al. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer. 2005;104(1):94–100.
   Web of Science ®Google Scholar
• Liu RR, Li MD, Li T, Tan Y, Zhang M, Chen JC. Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancer prognosis: a meta analysis. Int J Clin Exp Med. 2015;8(2):2261–2266.
   Web of Science ®Google Scholar
• Zhang L, Xi RX, Zhang XZ. Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer. Genet Mol Res. 2015;14(2):4616–4624.
   PubMed Web of Science ®Google Scholar
• Virós D, Camacho M, Zarraonandia I, et al. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. Oral Oncol. 2013;49(4):322–325.
   Web of Science ®Google Scholar
• Ogbureke KU, Weinberger PM, Looney SW, Li L, Fisher LW. Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget. 2012;3(3):286–298.
   Google Scholar
• Fraga CA, Farias LC, de Oliveira MV, et al. Increased VEGFR2 and MMP9 protein levels are associated with epithelial dysplasia grading. Pathol Res Pract. 2014;210(12):959–964.
   Web of Science ®Google Scholar
• Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol. 2009;45(8):647–653.
   PubMed Web of Science ®Google Scholar
• Zhou JH, Zhang B, Kernstine KH, Zhong L. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(10):1373–1378.
   Web of Science ®Google Scholar
• Ding H, Zhu Y, Chu T, Wang S. Epidermal growth factor induces FoxO1 nuclear exclusion to activate MMP7-mediated metastasis of larynx carcinoma. Tumour Biol. 2014;35(10):9987–9992.
   Google Scholar
• de Vicente JC, Lequerica-Fernandez P, Santamaria J, Fresno MF. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med. 2007;36(7):415–424.
   Web of Science ®Google Scholar
• Mäkinen LK, Häyry V, Atula T, et al. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J Oral Pathol Med. 2012;41(5):394–399.
   Web of Science ®Google Scholar
• Korpi JT, Kervinen V, Mäklin H, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008;98(4):766–775.
   Web of Science ®Google Scholar
• Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck. 2006;28(3):225–234.
   Web of Science ®Google Scholar
• Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 2006;25(1):115–136.
   Web of Science ®Google Scholar
• Shankar P, Kumar R, Singh DK, et al. Published database mining for MMP-3 inhibitors (natural and synthetic). World J Pharm Pharm Sci. 2015:4(10):1629–1637.
   Google Scholar
• Yamashita Y, Ishiguro Y, Sano D, et al. Antitumor effects of nafamostat mesilate on head and neck squamous cell carcinoma. Auris Nasus Larynx. 2007;34(4):487–491.
   Web of Science ®Google Scholar
• Hung SH, Shen KH, Wu CH, Liu CL, Shih YW. α-Mangostin suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling pathway. J Agric Food Chem. 2009;57(4):1291–1298.
   PubMed Web of Science ®Google Scholar
• Shih YW, Chien ST, Chen PS, Lee JH, Wu SH, Yin LT. α-Mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via αvβ3 integrin/FAK/ERK and NF-κB signaling pathway in human lung adenocarcinoma A549 cells. Cell Biochem Biophys. 2010;58(1):31–44.
   Web of Science ®Google Scholar
• Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M, Shirasuna K. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int J Cancer. 1998;77(4):578–585.
   Web of Science ®Google Scholar
• Suojanen J, Sorsa T, Salo T. Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro. Oral Dis. 2009;15(2):170–175.
   Web of Science ®Google Scholar
• Wen J, Nikitakis NG, Chaisuparat R, et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol. 2011;178(6):2866–2878.
   Web of Science ®Google Scholar
• Devel L, Czarny B, Beau F, Georgiadis D, Stura E, Dive V. Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1’ cavity. Biochimie. 2010;92(11):1501–1518.
   PubMed Web of Science ®Google Scholar
• Jacobsen JA, Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta. 2010;1803(1):72–94.
   PubMed Web of Science ®Google Scholar
• Czarny B, Stura EA, Devel L, et al. Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem. 2013;56(3):1149–1159.
   Web of Science ®Google Scholar
• Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517–1526.
   PubMed Web of Science ®Google Scholar
• Zhou N, Paemen L, Opdenakker G, Froyen G. Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (scFv). FEBS Lett. 1997;414(3):562–566.
   Web of Science ®Google Scholar
• García MP, Suárez-Peñaranda JM, Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM, García-García A. Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas: a therapeutic target? Cancer Lett. 2012;323(1):11–19.
   Web of Science ®Google Scholar
• Niu J, Huang Y, Zhang L. CXCR4 silencing inhibits invasion and migration of human laryngeal cancer Hep-2 cells. Int J Clin Exp Pathol. 2015;8(6):6255–6261.
   Web of Science ®Google Scholar
• Lee MH, Atkinson S, Rapti M, et al. The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Lett. 2010;290(1):114–122.
   Web of Science ®Google Scholar
• Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999;42(6):1140–1146.
   Google Scholar
• Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic [sic] family of compounds with promising therapeutic properties – review of the literature. Am J Physiol Cell Physiol. 2010;299(3):C539–C548.
   PubMed Web of Science ®Google Scholar
• García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol. 2005;67(4):1128–1136.
   PubMed Web of Science ®Google Scholar
• Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem. 2010;285(46):35944–3556.
   PubMed Web of Science ®Google Scholar
• Dufour A, Sampson NS, Li J, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011;71(14):4977–4988.
   PubMed Web of Science ®Google Scholar
• Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012;72(9):2339–2349.
   Web of Science ®Google Scholar
• Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett. 1996;397(2):277–282.
   Web of Science ®Google Scholar
• Mori H, Tomari T, Koshikawa N, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002;21(15):3949–3959.
   Web of Science ®Google Scholar
• Higashi S, Hirose T, Takeuchi T, Miyazaki K. Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). J Biol Chem. 2013;288(13):9066–9076.
   Web of Science ®Google Scholar
• Zhu L, Wang T, Perche F, Taigind A, Torchilin VP. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A. 2013;110(42):17047–17052.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yuan ZF, Wang Y, et al. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. J Am Chem Soc. 2013;135(13):5068–5073.
   PubMed Web of Science ®Google Scholar
• Chaudhary AK, Pandya S, Ghosh K, Nadkarni A. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res. 2013;753(1):7–23.
   Web of Science ®Google Scholar
• Eighth International Conference on the Chemistry and Biology of Mineralized Tissues. Proceedings of the 8th ICCBMT. Banff, Alberta, Canada. 2005. ICCBMT: https://iccbmt.mpikg.mpg.de/. Accessed March 20, 2017.
   Google Scholar